In collaboration with Novartis, we produced a 3D animation describing the mechanism of action Gleevec takes in the treatment of gastrointestinal stromal tumors (GISTs).

The majority of GISTs are caused by constitutively active signaling of the KIT receptor in cells of the gastrointestinal tract known as Interstitial Cells of Cajal (ICCs).

Gleevec competitively binds to the ATP-binding pocket of KIT receptors, preventing downstream signaling, thereby inhibiting cell growth and proliferation.